Submitted:
28 October 2024
Posted:
29 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Clinical Data
2.2. Histopathology
2.3. Immunohistochemistry
2.4. Electron Microscopy
2.5. Statistical Analysis
3. Results
3.1. Clinical Characteristics
3.2. Histopathological Findings
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Campanini, M.L.; Almeida, J.P.; Martins, C.S.; de Castro, M. The molecular pathogenesis of craniopharyngiomas. Arch Endocrinol Metab. 2023, 67, 266–275. [Google Scholar] [CrossRef] [PubMed]
- Cuny, T.; Buchfelder, M.; Dufour, H.; Grossman, A.; Gatta-Cherifi, B.; Jouanneau, E.; Raverot, G.; Vasiljevic, A.; Castinetti, F. The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal? Cancers 2022, 14, 3831–3846. [Google Scholar] [CrossRef] [PubMed]
- Müller, H.L.; Merchant, T.E.; Warmuth-Metz, M.; Martinez-Barbera, J.P.; Puget, S. Craniopharyngioma Nat. Rev. Dis. Primers. 2019, 5, 75–94. [Google Scholar] [CrossRef] [PubMed]
- Rushing, E.J.; Giangiaspero, F.; Paulus, W.; Burger, P.C. Craniopharyngioma. In World Health Organization classification of tumours: pathology and genetics of tumours of the Nervous System; Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Eds.; IARC Press: Lyon, France, 2007; pp. 238–240. [Google Scholar]
- Luo, S.P.; Zhang, H.W.; Yu, J.; Jiao, J.; Yang, J.H.; Leim, Y.; Lin, F. A rare case of giant cystic adamantinomatous craniopharyngioma in an adult. Radiol. Case Rep. 2020, 15, 846–849. [Google Scholar] [CrossRef]
- Louis, D.N.; Perry, A.; Wesseling, P.; Bratm, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; Soffietti, R.; von Deimling, A.; Ellison, D.W. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021, 23, 1231–1251. [Google Scholar] [CrossRef]
- Larkin, S.J.; Ansorge, O. Pathology and pathogenesis of Craniopharyngiomas. Pituitary 2013, 16, 9–17. [Google Scholar] [CrossRef]
- Fiorito, C.M.; Giglione, E.; Bellone, S.; Peretta, P.; Bertin, D.; Basso, M.E.; Bona, G. Craniopharyngioma in children: importance of a multidisciplinary approach and therapeutic strategies in the treatment of relapsing. Minerva Pediatr. 2013, 65, 673–676. [Google Scholar] [PubMed]
- Van Effenterre, R.; Boch, A.L. Craniopharyngioma in adults and children: a study of 122 surgical cases. J. Neurosurg. 2002, 97, 3–11. [Google Scholar] [CrossRef]
- Müller, H.L. Craniopharyngioma. Endocrine Reviews 2014, 35, 513–543. [Google Scholar] [CrossRef]
- Desiderio, C.; Martelli, C.; Rossetti, D.V.; Di Rocco, C.; D'Angelo.; L, Caldarelli, M.; Tamburrini, G.; Iavarone, F.; Castagnola, M.; Messana, I.; Cabras, T.; Faa, G. Identification of thymosins β4 and β 10 in paediatric craniopharyngioma cystic fluid. Childs. Nerv. Syst. 2013, 29, 951-60. [CrossRef]
- Barajas-Gómez, B.A.; Rosas-Carrasco, O.; Morales-Rosales, S.L.; Pedraza-Vázquez, G.; González-Puertos, V.Y; Juárez-Cedillo, T.; García-Álvarez, J.A.; López-Diazguerrero, N.E.; Damián-Matsumura, P.; Königsberg, M.; Luna-López, A. Relationship of inflammatory profile of elderly patients serum and senescence-associated secretory phenotype with human breast cancer cells proliferation: Role of IL6/IL8 ratio. Cytokine 2017, 91, 13–29. [Google Scholar] [CrossRef] [PubMed]
- Wang, P.; Konja, D.; Singh, S.; Zhang, B.; Wang, Y. Endothelial Senescence: From Macro- to Micro-Vasculature and Its Implications on Cardiovascular Health. Int. J. Mol. Sci. 2024, 25, 1978–1999. [Google Scholar] [CrossRef] [PubMed]
- Salminen, A.; Kauppinen, A.; Kaarniranta, K. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012, 24, 835–845. [Google Scholar] [CrossRef] [PubMed]
- Sato, K,; Kubota, T. Fine structure of ossification in Craniopharyngiomas. Ultrastruct Pathol. 1999, 23, 395–9. [CrossRef]
- Harada, H,; Takeuchi, K,; Nagata, Y,; Inoshita, N,; Ito, E,; Okumura, E,; Kondo, T,; Sato, Y,; Saito, R. A Case of Papillary Craniopharyngioma Mimicking Rathke's Cleft Cyst. NMC Case Rep J. 2024, 27:191-194. [CrossRef]
- Xu, C,; Wu, J,; Ye, J,; Si, Y,; Zhang, J,; Wu, B,; Pan, L,; Fu, J,; Ren, Q,; Xie, S,; Tang, B,; Xiao, Y,; Hong, T. Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization. Cell Death Dis. 2024,15:439. [CrossRef]
- Oka, H.; Kawano, N.; Yagishita, S.; Kobayashi, I.; Saegusa, H.; Fujii, K. Ciliated craniopharyngioma indicates histogenetic relationship to Rathke cleft epithelium. Clin. Neuropathol. 1997, 16, 103–106 PMID: 9101113. [Google Scholar] [PubMed]
- Vilches, J.; Lopez, A.; Martinez, M.C.; Gomez, J.; Barbera, J. Scanning and transmission electron microscopy of a craniopharyngioma: x-ray microanalytical study of the intratumoural mineralized deposits. Ultrastruct. Pathol. 1981, 2, 343–356. [Google Scholar] [CrossRef]
- Agozzino, L.; Ferraraccio, F.; Accardo, M.; Esposito, S.; Agozzino, M.; Cuccurullo, L. Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct. Pathol. 2006, 30, 143–150. [Google Scholar] [CrossRef]
- Zhu, J,; You, C. Craniopharyngioma: Survivin expression and ultrastructure. Oncol Lett. 2015, 9:75-80. [CrossRef]
- Szeifert, G.T.; Julow, J.; Szabolcs, M.; Slowik, F.; Bálint, K.; Pásztor, E. Secretory component of cystic craniopharyngiomas: a mucino-histochemical and electron-microscopic study. Surg. Neurol. 1991, 36, 286–293. [Google Scholar] [CrossRef]
- Kawano, N.; Oka, H.; Suwa, T.; Ito, H.; Yada, K.; Kameya, T.; Yagishita, S. Origin of craniopharyngioma: an electron microscopic study. Noshuyo Byori 1993, 10, 117–123 PMID: 8220791. [Google Scholar] [PubMed]
- Rumayor, A.; Carlos, R.; Kirsch, H.M.; de Andrade, B.A.; Romañach, M.J.; de Almeida, O.P. Ghost cells in pilomatrixoma, craniopharyngioma, and calcifying cystic odontogenic tumor: histological, immunohistochemical, and ultrastructural study. J. Oral Pathol. Med. 2015, 44, 284–290. [Google Scholar] [CrossRef]
- Castejón, O.J. Electron microscopic observations of endothelial junctions in perifocal human brain edema. An interpretative study. J. Submicrosc. Cytol. 1985, 17, 105–114 PMID: 3973952. [Google Scholar] [PubMed]
- Donson, A.M.; Apps, J.; Griesinger, A.M.; Amani, V.; Witt, D.A.; Anderson, R.C.; Niazi, T.N.; Grant, G.; Souweidane, M.; Johnston, J.M.; Jackson, E.M.; Kleinschmidt-DeMasters, B.K.; et al. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. J. Neuropathol. Exp. Neurol. 2017, 76, 779–788. [Google Scholar]
- Sun, Y.; Zeng, X.R.; Wenger, L.; Cheung, H.S. Basic calcium phosphate crystals stimulate the endocytotic activity of cells--inhibition by anti-calcification agents. Biochem. Biophys. Res. Commun. 2003, 312, 1053–1059. [Google Scholar] [CrossRef] [PubMed]
- Terlecki-Zaniewicz, L,; Lämmermann, I,; Latreille, J,; Bobbili, MR,; Pils, V,; Schosserer, M,; Weinmüllner, R,; Dellago, H,; Skalicky, S,; Pum, D,; Almaraz, JCH,; Scheideler, M,; Morizot, F;, Hackl, M,; Gruber, F,; Grillari, J.; Small extracellular vesicles and their miRNA cargo are anti-apoptotic members of the senescence-associated secretory phenotype. Aging (Albany NY). 2018, 10:1103-1132. [CrossRef]
- Azari, F.; Vali, H.; Guerquin-Kern, J.L; Wu, T.D.; Croisym, A.; Sears, S.K.; Tabrizian, M.; McKee, M.D. Intracellular precipitation of hydroxyapatite mineral and implications for pathologic calcification. J. Struct. Biol. 2008, 162, 468–479. [Google Scholar] [CrossRef]
- Song-Tao, Q,; Xiao-Rong, Y,; Jun, P,; Yong-Jian, D,; Jin, L,; Guang-Long, H,; Yun-Tao, L,; Jian, R,; Xiang-Zhao, L,; Jia-Ming, X. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis? Histopathology. 2014, 64:336-47. [CrossRef]
- Qi, S.; Huang, G.; Pan, J.; Li, J.; Zhang, X.; Fang, L.; Liu, B.; Meng, W.; Zhang, Y.; Liu, X. Involvement of osteopontin as a core protein in craniopharyngioma calcification formation. J. Neurooncol. 2010, 98, 21–30. [Google Scholar] [CrossRef]
- Peng, J,; Qi, S,; Pan, J,; Zhang, X,; Huang, G,; Li, D. Preliminary Study on Composition and Microstructure of Calcification in Craniopharyngiomas. J Craniofac Surg. 2016, 27:e409-13. [CrossRef]
- iachelli, CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005, 8:229-31. [CrossRef]
- Giachelli, CM. Ectopic calcification: new concepts in cellular regulation. Z Kardiol. 2001;90 Suppl 3:31-7. [CrossRef]
- Huang, Z,; Zhang Z,, Zhou, C,; Liu, L,; Huang, C. Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm. 2022 3:e144. [CrossRef]
- Qi, ST,; Zhou, J,; Pan, J,; Zhang, C,; Silky, C,; Yan, XR. Epithelial-mesenchymal transition and clinicopathological correlation in craniopharyngioma. Histopathology. 2012, 61:711-25. [CrossRef]
- Iwatsuki, M,; Mimori, K,; Yokobori, T,; Ishi, H,; Beppu, T,; Nakamori, S,; Baba, H,; Mori, M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101:293-9. [CrossRef]
- Gonzalez-Meljem, J.M.; Martinez-Barbera, J.P. Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis. Cell Mol. Life Sci. 2021, 78, 4521–4544. [Google Scholar] [CrossRef]
- Chambers, C.R.; Ritchie, S.; Pereira, B.A.; Timpson, P. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. Mol Oncol. 2021, 15, 3242–3255. [Google Scholar] [CrossRef]
- Gonzalez-Meljem, JM,; Haston, S,; Carreno, G,; Apps, JR,; Pozzi, S,; Stache, C,; Kaushal, G,; Virasami, A,; Panousopoulos, L,; Mousavy-Gharavy, SN,; Guerrero, A,; Rashid, M,; Jani, N,; Goding, CR,; Jacques, TS,; Adams, DJ,; Gil, J,; Andoniadou, CL,; Martinez-Barbera, JP. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nat Commun. 2017, 8:1819. [CrossRef]
- Donson, AM,; Apps, J,; Griesinger, AM,; Amani, V,; Witt, DA,; Anderson, RCE,; Niazi, TN,; Grant, G,; Souweidane, M,; Johnston, JM,; Jackson, EM,; Kleinschmidt-DeMasters, BK,; Handler, MH,; Tan, AC,; Gore, L,; Virasami, A,; Gonzalez-Meljem, JM,; Jacques, TS,; Martinez-Barbera, JP,; Foreman, NK,; Hankinson, TC. Advancing Treatment for Pediatric Craniopharyngioma Consortium. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. J Neuropathol Exp Neurol. 2017, 76:779-788.
- Desiderio, C,; Rossetti, DV,; Castagnola, M,; Massimi, L,; Tamburrini, G. Adamantinomatous craniopharyngioma: advances in proteomic research. Childs Nerv Syst. 2021, 37:789-797. [CrossRef]
- Gonzalez-Meljem, JM,; Martinez-Barbera, JP. Implications of cellular senescence in paediatric pituitary tumours. EBioMedicine. 2024, 99:104905. [CrossRef]
- Rodier, F,; Campisi, J. Four faces of cellular senescence. J Cell Biol. 2011, 192(4):547-56. [CrossRef]
- Malaquin, N,; Martinez, A,; Rodier, F. Keeping the senescence secretome under control: Molecular reins on the senescence-associated secretory phenotype. Exp Gerontol. 2016, 82:39-49. [CrossRef]
- Watanabe, S,; Kawamoto, S,; Ohtani, N,; Hara E. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci. 2017, 108:563-569. [CrossRef]
- Ritschka, B.; Storer, M.; Mas, A.; Heinzmann, F.; Ortells, M.C.; Morton, J.P.; Sansom, O.J.; Zender, L.; Keyes, W.M. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 2017, 31, 172–183. [Google Scholar] [CrossRef]
- Song, S,; Lam, EW,; Tchkonia, T,; Kirkland, JL,; Sun, Y. Senescent Cells: Emerging Targets for Human Aging and Age-Related Diseases. Trends Biochem Sci. 2020, 45:578-592. [CrossRef]
- Carreno, G.; Guiho, R.; Martinez-Barbera, J.P. Cell senescence in neuropathology: A focus on neurodegeneration and tumours. Neuropathol. Appl. Neurobiol. 2021, 47, 359–378. [Google Scholar] [CrossRef]

| EE | SR | WK | DC | WLA | ABT | V | RFs | |
|---|---|---|---|---|---|---|---|---|
| CK5/6 | +++ | ++ | + | + | ++ | --- | --- | --- |
| CK8 | ++ | ++ | + | -- | + | --- | --- | --- |
| AE1/3 | + | -- | --- | --- | --- | --- | --- | --- |
| EMA | ++ | ++ | + | -- | + | --- | --- | --- |
| Claudin 5 | + | + | + | - | + | --- | --- | --- |
| N-cadherin | ++ | + | + | + | + | --- | --- | --- |
| E-Cadherin | +++ | ++ | + | + | ++ | + | --- | --- |
| B-cat | ++ | + | + | + | *** | + | --- | --- |
| EGFR, | + | + | + | + | + | + | + | -- |
| PDGFR-beta | --- | --- | + | + | + | + | + | -- |
| BFGF | --- | --- | + | + | + | + | --- | --- |
| GFAP | +++ | --- | --- | --- | --- | +++ | --- | + |
| Nestin | --- | --- | --- | --- | --- | --- | + | --- |
| Osteonectin | --- | --- | + | + | + | --- | --- | --- |
| Osteopontin | --- | --- | + | + | + | --- | --- | --- |
| CD34 | + | + | + | + | + | +++ | + | --- |
| AdaCps N=26 (%) |
PaCPs N=2(%) |
Recurrence N=15(%) |
Non-recurrence N=13(%) |
|
|---|---|---|---|---|
| Cyts formation | 8(31%) | 0 | 8(53%) | 5(38%) |
| Solid stellate reticulum | 9(35%) | 2(100) | 7(47%) | 3(23%) |
| Atypia in EE | 7(27%) | 0 | 5(33%) | 2(15%) |
| Atypia in SR | 7(27%) | 0 | 5(33%) | 2(15%) |
| Mitosis figures | 7(27%) | 0 | 5(33%) | 2(15%) |
| Metaplastic changes | 7(27%) | 0 | 5(33%) | 2(15%) |
| Wet keratin | 17(65%) | 0 | 15(100%) | 2(15%) |
| Dystrophic calcification | 24(92%) | 0 | 15(100%) | 9(69%) |
| Sword like arrays | 26(100%) | 0 | 13(87%) | 5(35%) |
| Inflammation | 26(100%) | 0 | 15(100%) | 8(62%) |
| Macrophages | 20(77%) | 0 | 15(100%) | 5(38%) |
| Granuloma formation | 8(31%) | 0 | 8(53%) | 0 |
| Cleft cholesterol | 9(35%) | 0 | 7(47%) | 2(15%) |
| Reactive gliosis | 22(85%) | 1(50%) | 15(100%) | 2(15%) |
| Rosenthal Fibers | 20(77%) | 1(50%) | 15(100%) | 0 |
| Nest form of invasión | 26(100%) | 0 | 15(100%) | 5(38%) |
| DC form of invasión | 20(77%) | 0 | 13(87%) | 5(38%) |
| Necrosis | 7(27%) | 0 | 3(20%) | 0 |
| Clinical data | Recurrence Tumors 15 (54%) |
Non- recurrence Tumors 13 (46%) |
P value |
|---|---|---|---|
| Age (years) | 31 | 33 | .051 |
| Female Male |
9 6 |
3 10 |
.757 |
| Patient weight | 80 | 75 | .186 |
| Diabetes mellitus | 7 | 3 | .184 |
| Time of onset of symptoms (months) | 7.7 | 9 | .443 |
| Tumor’s size (mm) | 42 | 24 | .004 |
| Progression-free survival (months) | 5 | 12 | .000 |




| Clinical data | Recurrence Tumors 15 (54%) |
Non- recurrence Tumors 13 (46%) |
P value |
|---|---|---|---|
| Age (years) | 31 | 33 | .051 |
| Female Male |
9 6 |
3 10 |
.757 |
| Patient weight | 80 | 75 | .186 |
| Diabetes mellitus | 7 | 3 | .184 |
| Time of onset of symptoms (months) | 7.7 | 9 | .443 |
| Tumor’s size (mm) | 42 | 24 | .004 |
| Progression-free survival (months) | 5 | 12 | .000 |
| AdaCps N=26 (%) |
PaCPs N=2(%) |
Recurrence N=15(%) |
Non-recurrence N=13(%) |
|
|---|---|---|---|---|
| Cyts formation | 8(31%) | 0 | 8(53%) | 5(38%) |
| Solid stellate reticulum | 9(35%) | 2(100) | 7(47%) | 3(23%) |
| Atypia in EE | 7(27%) | 0 | 5(33%) | 2(15%) |
| Atypia in SR | 7(27%) | 0 | 5(33%) | 2(15%) |
| Mitosis figures | 7(27%) | 0 | 5(33%) | 2(15%) |
| Metaplastic changes | 7(27%) | 0 | 5(33%) | 2(15%) |
| Wet keratin | 17(65%) | 0 | 15(100%) | 2(15%) |
| Dystrophic calcification | 24(92%) | 0 | 15(100%) | 9(69%) |
| Sword like arrays | 26(100%) | 0 | 13(87%) | 5(35%) |
| Inflammation | 26(100%) | 0 | 15(100%) | 8(62%) |
| Macrophages | 20(77%) | 0 | 15(100%) | 5(38%) |
| Granuloma formation | 8(31%) | 0 | 8(53%) | 0 |
| Cleft cholesterol | 9(35%) | 0 | 7(47%) | 2(15%) |
| Reactive gliosis | 22(85%) | 1(50%) | 15(100%) | 2(15%) |
| Rosenthal Fibers | 20(77%) | 1(50%) | 15(100%) | 0 |
| Nest form of invasión | 26(100%) | 0 | 15(100%) | 5(38%) |
| DC form of invasión | 20(77%) | 0 | 13(87%) | 5(38%) |
| Necrosis | 7(27%) | 0 | 3(20%) | 0 |
| EE | SR | WK | DC | WLA | ABT | V | RFs | |
|---|---|---|---|---|---|---|---|---|
| CK5/6 | +++ | ++ | + | + | ++ | --- | --- | --- |
| CK8 | ++ | ++ | + | -- | + | --- | --- | --- |
| AE1/3 | + | -- | --- | --- | --- | --- | --- | --- |
| EMA | ++ | ++ | + | -- | + | --- | --- | --- |
| Claudin 5 | + | + | + | - | + | --- | --- | --- |
| N-cadherin | ++ | + | + | + | + | --- | --- | --- |
| E-Cadherin | +++ | ++ | + | + | ++ | + | --- | --- |
| B-cat | ++ | + | + | + | *** | + | --- | --- |
| EGFR, | + | + | + | + | + | + | + | -- |
| PDGFR-beta | --- | --- | + | + | + | + | + | -- |
| BFGF | --- | --- | + | + | + | + | --- | --- |
| GFAP | +++ | --- | --- | --- | --- | +++ | --- | + |
| Nestin | --- | --- | --- | --- | --- | --- | + | --- |
| Osteonectin | --- | --- | + | + | + | --- | --- | --- |
| Osteopontin | --- | --- | + | + | + | --- | --- | --- |
| CD34 | + | + | + | + | + | +++ | + | --- |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).